Endometrial cancer risk is rising, especially among premenopausal women, with diet and lifestyle factors playing a central ...

GlaxoSmithKline Pharmaceuticals has entered the oncology segment in India, introducing Jemperli and Zejula for gynaecological ...

GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies ...

GlaxoSmithKline Pharmaceuticals has launched Jemperli and Zejula in India, pioneering precision therapies for gynaecological ...

GSK India has launched Jemperli and Zejula for gynaecological cancers, marking its return to oncology a decade after ...

GSK enters oncology with Jemperli & Zejula for gynaecological cancers in India. Advanced therapies address unmet needs in ...

Bhushan Akshikar, Managing Director of GSK India, said the company is committed to making these therapies accessible through a tiered pricing strategy and a comprehensive patient support program ...

Jemperli is the first and only approved programmed death receptor-1 (PD-1) immunotherapy for the second-line treatment of ...

GlaxoSmithKline (GSK) on Monday announced its foray into the Indian oncology market with the launch of two precision ...

GlaxoSmithKline Pharmaceuticals said it is bringing in Jemperli and Zejula to India, marking its re-entry into the cancer ...

Karen Thursby, a Darlington -based yoga teacher who lost her mother Lola to bile duct cancer in 2017, has been organising ...